This article does not advertise a prescription-only medicine or imply that a named treatment is available from the clinic. Treatment decisions require an individual medical consultation.
Do the medicines work in the same way?
They overlap in GLP-1 receptor activity, but tirzepatide also activates the GIP receptor.
This pharmacological difference may affect average outcomes and adverse effects, but it does not remove the need for an individual assessment.
Did a head-to-head trial find a difference?
Yes. A randomised head-to-head trial in adults with obesity but without diabetes reported greater average weight reduction with tirzepatide than semaglutide over 72 weeks.
The trial studied a defined population under a research protocol and was industry sponsored. Its mean results do not tell a particular patient which treatment will be safer, more tolerable or more effective for them.
How should a treatment decision be made?
The decision should consider the licensed indication, health history, contraindications, interactions, reproductive plans, adverse-effect profile and response over time.
This educational comparison does not imply that either medicine is available from Dr K Medical Wellness.
Frequently asked questions
There is no universally best option. Suitability depends on the person and may change during treatment.
No. Averages describe groups and cannot guarantee an individual benefit or adverse-effect experience.
References
- National Institute for Health and Care Excellence. Overweight and obesity management (NG246). 8 January 2026. UK clinical guideline. Accessed 12 June 2026.
- New England Journal of Medicine. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. 11 May 2025. Peer-reviewed randomised controlled trial. DOI: 10.1056/NEJMoa2416394. Accessed 12 June 2026.